Abstract CT025: JS203, a CD20×CD3 bispecific antibody with a 2:1 structure, demonstrated promising responses in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) in a phase I study
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institutions: Peking University, Peking University Cancer Hospital, Fujian Provincial Cancer Hospital, Peking University Third Hospital, Zhejiang Cancer Hospital, Sichuan Cancer Hospital, Henan Cancer Hospital, Jiangxi Provincial Cancer Hospital, Sichuan University, West China Hospital of Sichuan University, Second Affiliated Hospital of Nanchang University, Tianjin First Center Hospital, Second Hospital of Shandong University, Shandong First Medical University, The Affiliated Yongchuan Hospital of Chongqing Medical University, First Hospital of China Medical University, Junshi Biosciences (China)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409822357